LegaLogic advises Ahammune Biosciences - funding from Ideaspring Capital, IAN, Kotak Private Equity, Dr. Anand Deshpande and others
LegaLogic Consulting advised Ahammune Biosciences (http://www.ahammune.com/) in Pre-Series A funding.
Pre-Series A round was led by Ideaspring Capital and Indian Angel Network. Kotak Private Equity, Legacy Assets LLP (Baldota family fund) and Mr. Ajith Kamath (ex-Pfizer) also participated in the round along with the existing investors Dr. Anand Deshpande and Mr. Suman Kant Munjal.
Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Ahammune’s current program is on the depigmenting disorder, Vitiligo.
LegaLogic (www.LegaLogic.co.in) was the sole legal counsel for Ahammune Bioscienes and advised on structuring the deal, review and finalization of deal documentation and closing assistance.
Team – Partners –Vikas Agarwal and Vivek Sadhale, Senior Legal Advisors – Siddhesh Iyer, Sakshi Kalra and Legal Advisor – Pranav Divgi
14 May 2021